Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2026 16:05 ET | Source: Turn Therapeutics

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for...
January 07, 2026 11:40 ET | Source: Research and Markets

Glabellar Frown Lines Market Analysis and Demand Forecast, 2025-2035, with Regional Insights

Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The "Glabellar Frown Lines Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 05, 2026 17:00 ET | Source: Alumis Inc.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
December 29, 2025 09:00 ET | Source: American Society for Dermatologic Surgery

Dermatologic Surgery Journal Releases Special Issue on Facial Assessment in a Diverse World

Schaumburg, IL, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Dermatologic Surgery, the official scientific journal of the American Society for Dermatologic Surgery (ASDS), has published a special issue on...
December 23, 2025 05:00 ET | Source: InnoCare Pharma

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
December 17, 2025 13:00 ET | Source: American Society for Dermatologic Surgery

Kavita Mariwalla, MD, Begins ASDS/A Presidential Year

Schaumburg, IL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to introduce its new President, Kavita Mariwalla, MD, who began serving her one-year...
December 14, 2025 04:49 ET | Source: InnoCare Pharma

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.
December 10, 2025 08:30 ET | Source: Journey Medical Corporation

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...
November 28, 2025 00:28 ET | Source: SNS Insider pvt ltd

Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Atopic Dermatitis Drugs Market Size & Growth Analysis According to by SNS Insider, the Atopic Dermatitis Drugs Market size was valued at USD 14.93...